This version of the registration was submitted prior to the Lobbying Transparency Act coming into force on May 4, 2020. Due to different information requirements at that time, the registration is presented in the following format.
Registration ID: 789798 Submitted by lobbyist on: May 28, 2018 08:56:00 AM Accepted by Registrar on: May 28, 2018 09:48:59 AM
Designated Filer Information
Keon, James J
4120 Yonge Street Suite 409
Toronto, ON, M2P 2B8
416-223-2333
Canada
Organization Information
Canadian Generic Pharmaceutical Association (CGPA)
The CGPA's mission is to promote an environment which supports and enhances the provision of affordable generic medications to Canadians and patients around the world. The Association researches and develops positions regarding a wide variety of policies, regulations and legislation that affects our member companies. We promote our sector's interests by publishing material as well as directly contacting government officials, the media and other opinion leaders and decision makers.
4120 Yonge Street Suite 409
Toronto, BC, M2P 2B8
416-223-2333
Canada
Relevant Affiliates
The client has no relevant affiliates.
Government or Government Agency Funding
The organization does not receive any funding from a government or government agency.
Other Controlling or Directing Interests
The organization has no other controlling or directing interests.
Active Registration Period
May 28, 2018
November 28, 2018
Organization's In-House Lobbyists
Name:
Connell, Jeff
May 28, 2018
Inactivation Date:
December 16, 2018
BC Public Office Background
This individual has not held any public office positions in BC.
Lobbying Activities
Health
Awarding, amendment or termination of a contract, grant or financial benefit
Development, establishment, amendment or termination of any program, policy or decision
Introduction, modification or repeal of legislation, a bill or regulation
Developing a regulatory pathway for biosimilars. Addressing use of brand coupon cards. Protecting the interests of Canada's generic pharmaceutical industry during implementation of the Comprehensive Economic and Trade Agreement. Implementation of commitments made by British Columbia pursuant to its involvement with the pan-Canadian Pharmaceutical Alliance. Use of Ontario reference price. Amendment of the Drug Price Regulation in respect of the Maximum Allowable List Price to bring it in line with pCPA tiered pricing model and elimination of exclusive listings. Payment of distribution fees by the government. Promoting greater utilization of generic prescription medicines. Price increase policy. Scope of listings. National Pharmacare initiative.
Target Contacts
Target Type
Name
Title or Constituency
Date Added
Minister
Dix,
Adrian
Minister of Health
May 28, 2018
Public Agency
Health
May 28, 2018
Name:
Cox, Jody
May 28, 2018
Inactivation Date:
December 16, 2018
BC Public Office Background
This individual has not held any public office positions in BC.
Lobbying Activities
International Trade
Development, establishment, amendment or termination of any program, policy or decision
Protecting the interests of Canada's generic pharmaceutical industry during implementation of the Comprehensive Economic and Trade Agreement. Canadian negotiating position with United States regarding intellectual property protection for pharmaceutical and biosimilar drugs in trade negotiations. Canadian negotiating position with United States regarding intellectual property protection for pharmaceutical and biosimilar drugs in trade negotiations.
Target Contacts
Target Type
Name
Title or Constituency
Date Added
Public Agency
Minister of State for Trade
May 28, 2018
Name:
Keon, James
May 28, 2018
Inactivation Date:
December 16, 2018
BC Public Office Background
This individual has not held any public office positions in BC.
Lobbying Activities
Health
Awarding, amendment or termination of a contract, grant or financial benefit
Development, establishment, amendment or termination of any program, policy or decision
Introduction, modification or repeal of legislation, a bill or regulation
Developing a regulatory pathway for biosimilars. Addressing use of brand coupon cards. Protecting the interests of Canada's generic pharmaceutical industry during implementation of the Comprehensive Economic and Trade Agreement. Implementation of commitments made by British Columbia pursuant to its involvement with the pan-Canadian Pharmaceutical Alliance. Use of Ontario reference price. Amendment of the Drug Price Regulation in respect of the Maximum Allowable List Price to bring it in line with pCPA tiered pricing model and elimination of exclusive listings. Payment of distribution fees by the government. Promoting greater utilization of generic prescription medicines. Price increase policy. Scope of listings. National Pharmacare initiative.
